These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 3123602)

  • 1. Current controversies in the use of selegiline hydrochloride.
    Lees AJ
    J Neural Transm Suppl; 1987; 25():157-62. PubMed ID: 3123602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selegiline for Parkinson's disease.
    Calesnick B
    Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-(-)-deprenyl as an adjuvant to levodopa in the treatment of Parkinson's disease.
    Rinne UK
    J Neural Transm Suppl; 1987; 25():149-55. PubMed ID: 3123601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline in the early and late phases of Parkinson's disease.
    Csanda E; Tárczy M
    J Neural Transm Suppl; 1987; 25():105-13. PubMed ID: 3123597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with selegiline in the treatment of Parkinson's disease.
    Poewe W; Gerstenbrand F; Ransmayr G
    J Neural Transm Suppl; 1987; 25():131-5. PubMed ID: 3123599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. R-(-)-deprenyl as a possible protective agent in Parkinson's disease.
    Tetrud JW; Langston JW
    J Neural Transm Suppl; 1987; 25():69-79. PubMed ID: 3123606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oscillations in performance in levodopa-treated parkinsonians: treatment with bromocriptine and L-deprenyl.
    Lander CM; Lees A; Stern G
    Clin Exp Neurol; 1979; 16():197-203. PubMed ID: 121706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
    Birkmayer W; Birkmayer GD
    J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
    Golbe LI; Duvoisin RC
    J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. L-deprenyl in the treatment of Parkinson's disease.
    Csanda E; Tárczy M; Takáts A; Mogyorós I; Köves A; Katona G
    J Neural Transm Suppl; 1983; 19():283-90. PubMed ID: 6421993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deprenyl in the treatment of Parkinson's disease. A specific type B monoamine oxidase inhibitor.
    Lieberman AN; Gopinathan G; Neophytides A; Hiesiger E; Nelson J; Walker R; Goodgold A
    N Y State J Med; 1984 Jan; 84(1):13-6. PubMed ID: 6422358
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution].
    Amato L; Nava L; Rizzo M; Piccoli F
    Riv Neurol; 1985; 55(1):46-52. PubMed ID: 3927468
    [No Abstract]   [Full Text] [Related]  

  • 16. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
    Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
    J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of MAO-b inhibitors in the treatment of Parkinson's disease.
    Ruggieri S; Stocchi F; Denaro A; Baronti F; Agnoli A
    J Neural Transm Suppl; 1986; 22():227-33. PubMed ID: 3097257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (-)Deprenyl in the treatment of decompensated Parkinson's disease.
    Csanda E; Tárczy M; Takáts A
    J Neural Transm Suppl; 1986; 22():247-52. PubMed ID: 3097259
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New approaches in the use of selegiline for the treatment of Parkinson's disease.
    Lees AJ; Frankel J; Eatough V; Stern GM
    Acta Neurol Scand Suppl; 1989; 126():139-45. PubMed ID: 2515719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.